<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121143</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1314-202</org_study_id>
    <nct_id>NCT04121143</nct_id>
  </id_info>
  <brief_title>A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults</brief_title>
  <official_title>Multicenter, Placebo-controlled, Parallel-randomized, Double-blind, Phase II Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of SHR-1314 Injection With Moderate to Severe Plaque Psoriasis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, placebo-controlled, parallel-randomized, double-blind, phase II study
      to investigate the efficacy, safety, tolerability and Pharmacokinetics of SHR-1314 injection
      with moderate to severe plaque psoriasis in adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a multicenter, parallel, randomized, double-blind, placebo-controlled clinical
      trial designed to evaluate the efficacy ,safety, tolerance, and pharmacokinetics (PK) of
      different SHR-1314 dosing regimens in moderate to severe chronic plaque psoriasis in adults.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    sponsor's decision
  </why_stopped>
  <start_date type="Actual">November 9, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects reach to PASI 75 response at 16 weeks</measure>
    <time_frame>16 week</time_frame>
    <description>Proportion of subjects with a Psoriatic Area and Severity Index (PASI) score improved by at least 75% (to achieve a PASI 75 response) relative to the baseline PASI score at Week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PASI 90 response at week 16</measure>
    <time_frame>16 week</time_frame>
    <description>Proportion of subjects with a Psoriatic Area and Severity Index (PASI) score improved by at least 90% (to achieve a PASI 90 response) relative to the baseline PASI score at Week 16 will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SHR-1314 low dose short intervals of subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SHR-1314 high dose long intervals of subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SHR-1314 high dose short intervals of subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was subcutaneously injected into the 16 weeks turnover SHR-1314 subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-17A Antagonist</intervention_name>
    <description>SHR-1314 subcutaneous injection</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_label>Treatment group C</arm_group_label>
    <other_name>SHR-1314</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>placebo subcutaneous injection to maintain consistency and to prevent blindness</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

          -  Provide written informed consent before any study assessment is performed.

          -  Male or female at least 18 years of age at screening.

          -  Chronic plaque psoriasis history ≥ 6 months;At the time of randomization, moderate to
             severe plaque psoriasis.

          -  Subject is a candidate for systemic psoriasis therapy and/or phototherapy and/or chemo
             phototherapy.

          -  The body mass index (BMI) was ≥18 kg/m2 and ≤35 kg/m2 at screening.

          -  Exclusion Criteria:

          -  Diagnosis of psoriasis at screening is not chronic plaque psoriasis

          -  Severe infection or systemic infection before baseline

          -  There are other skin problems that researchers believe will hinder the evaluation of
             psoriasis.

          -  Subject has a history or symptom of malignancy within 5 years prior to screening,
             regardless of whether or not treatment has been received, with or without signs of
             recurrence or metastasis.

          -  The investigators believe that the subject is not suitable for any clinical condition
             involved in the clinical study.

          -  Those who are allergic to the study ingredients or excipients, or who are allergic to
             other biological agents.

          -  There is evidence that hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
             confirmation test is positive.

          -  Subject's medical history, symptoms and examination results suggest active
             tuberculosis or latent tuberculosis.

          -  Laboratory tests have clinical implications at screening, and the investigators
             believe that participation in the study may pose unacceptable risks to the subject or
             impede data analysis.

          -  Women who are pregnant or breastfeeding at screening or at baseline

          -  The investigator believes that it will prevent the subject from following and
             completing any other circumstances of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Hengrui Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200122</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

